Correction to: Combining the differentiating effect of panobinostat with the apoptotic effect of arsenic trioxide leads to significant survival benefit in a model of t(8;21) acute myeloid leukemia

Clinical Epigenetics
Jessica M SalmonRicky W Johnstone

Abstract

An amendment to this paper has been published and can be accessed via the original article.

Methods Mentioned

BETA
Flow cytometry

Related Concepts

Related Feeds

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

Related Papers

BMC Public Health
Guillermo Salinas-EscuderoJuan Garduño-Espinosa
World Journal of Surgical Oncology
Antoni Lluecaon behalf MUAPOS Working Group
© 2021 Meta ULC. All rights reserved